Bipolar spectrum

Global Bipolar Depression Market Insight, Epidemiology and Market Forecast 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical, Health, Mental health, Psychiatric diagnosis, Psychiatry, Mind, Psychology, Mood disorders, Depression, Mood stabilizers, Bipolar spectrum, Bipolar disorder, Bipolar I disorder, Major depressive disorder, Lurasidone

The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Bipolar Depression - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Bipolar Depression epidemiology division provides insights about the historical and current Bipolar Depression patient pool and forecasted trends for every seven major countries.
  • In 2013, lurasidone was approved as a monotherapy and adjunct to ongoing lithium or valproate for bipolar I depression.

Mantra Health Adds Bipolar I Disorder to its Telepsychiatry Treatments Helping College Students Get Diagnosed and Treated Early

Retrieved on: 
Wednesday, July 14, 2021
Psychiatry, Psychiatric diagnosis, Depression, Mood disorders, Abnormal psychology, Bipolar spectrum, Bipolar disorder, Bipolar I disorder, Bipolar II disorder, Bipolar, Telepsychiatry, Mental disorder

Mantra Health already supports bipolar II disorder through its collaborative telepsychiatry program and has seen successful outcomes in the 2020-2021 school year.

Key Points: 
  • Mantra Health already supports bipolar II disorder through its collaborative telepsychiatry program and has seen successful outcomes in the 2020-2021 school year.
  • Building on that success and recognizing there's a lack of care for students with Serious Mental Illnesses (SMIs) on college campuses, Mantra Health has added bipolar I disorder treatment to its program.
  • Bipolar disorder affects about 2.8% of the population in the U.S. overall, but roughly 3.2% of college students .
  • Adding treatment of bipolar I disorder doesn't change the extensive protocols around safety and risk that Mantra Health already has in place for students.

Annals of Family Medicine: Psychotherapy and Pharmacotherapy are More Effective in Treating Depression when Paired Together in Primary Care

Retrieved on: 
Tuesday, May 11, 2021
Major depressive disorder, Psychiatric diagnosis, Psychotherapy, Pharmacotherapy, Management of depression, Antidepressant, Psychiatry, Medicine, Clinical medicine, Bipolar spectrum, Mood disorders, Dysthymia

b'ANN ARBOR, Mich., May 11, 2021 /PRNewswire/ -- Most patients with depression are treated in primary care, and the majority of those patients prefer psychotherapy over treatment that includes medication (i.e., pharmacotherapy).

Key Points: 
  • b'ANN ARBOR, Mich., May 11, 2021 /PRNewswire/ -- Most patients with depression are treated in primary care, and the majority of those patients prefer psychotherapy over treatment that includes medication (i.e., pharmacotherapy).
  • Primary care physicians, however, are more likely to prescribe antidepressants to their patients suffering from depression.\nAlthough studies have shown the effectiveness of psychotherapy in primary care patients, researchers haven\'t yet examined the effects of psychotherapy compared with pharmacotherapy, combined treatment, and other clinical scenarios in primary care.\nIn a study published in the May/June, 2021 issue of Annals of Family Medicine, researchers examined the effects of psychotherapy compared with pharmacotherapy, combined treatment, care-as-usual, waitlist, and pill placebo in primary care patients.\nThe study is led by Pim Cuijpers, Ph.D., professor of clinical psychology in the Department of Clinical, Neuro and Development Psychology at Vrije Universiteit, The Netherlands, and includes collaborating authors from Japan, Spain, the U.K. and New Zealand.\nThe team integrated the results of 58 randomized controlled trials involving 9,301 patients.
  • "Treatments in primary care must be organized so as to accommodate any of these treatments in response to patients\' preferences and values.
  • "\nPsychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis\nVrije Universiteit Amsterdam, Department of Clinical, Neuro and Developmental Psychology; Amsterdam Public Health Research Institute; Vrije Universiteit, Amsterdam, The Netherlands.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/annals-of-family-medicine-psycho...\n'

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

Retrieved on: 
Monday, May 3, 2021
Psychiatric diagnosis, Mood disorders, Psychiatry, Abnormal psychology, Depression, Bipolar spectrum, Emotion, Bipolar disorder, Treatment of bipolar disorder, Bipolar I disorder, Bipolar II disorder, Psychosis

Bipolar I and Bipolar II each represent about half of the overall population of patients with bipolar disorder.\nBipolar depression is the most common clinical presentation of bipolar disorder.

Key Points: 
  • Bipolar I and Bipolar II each represent about half of the overall population of patients with bipolar disorder.\nBipolar depression is the most common clinical presentation of bipolar disorder.
  • Bipolar depression remains a significantly underserved medical need, with only a few\xc2\xa0FDA-approved treatment options available.
  • These treatments are commonly associated with tolerability issues.\nCAPLYTA\xc2\xae (lumateperone) is under investigation for the treatment of bipolar disorder.
  • CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.\nContraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA.

In Recognition of World Bipolar Day, Novelist and Mental Health Advocate Susan Sofayov Releases DEFECTIVE on Kindle Unlimited

Retrieved on: 
Tuesday, March 30, 2021
Psychiatric diagnosis, Depression, Mood disorders, Bipolar spectrum, Psychiatry, Human behavior, Bipolar disorder, Bipolar

PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- To commemorate World Bipolar Day, award-winning author Susan Dobransky-Sofayov announces that her novel, Defective, has been released on Kindle Unlimited.

Key Points: 
  • PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- To commemorate World Bipolar Day, award-winning author Susan Dobransky-Sofayov announces that her novel, Defective, has been released on Kindle Unlimited.
  • Defective is the story of an aspiring young law student coming to terms with her newly-discovered Bipolar II diagnosis in the midst of a crumbling romantic relationship.
  • Defective follows University of Pittsburgh law student Maggie Hovis, who battles to hold on to her fianc, her grade point average, and her own sanity as she unknowingly deals with Bipolar II Disorder.
  • Defective shows the daily reality faced by people, particularly young women, who may not even be aware that their challenges are related to Bipolar Disorder.

Author R.B. Le'Deach's new book "Personality Disorder Not Otherwise Specified: Confessions of a Bipolar Patient" is a deeply personal memoir of his challenging life

Retrieved on: 
Thursday, March 25, 2021
Psychiatric diagnosis, Depression, Mood disorders, Psychiatry, Bipolar spectrum, Bipolar disorder, Human behavior, Psychology, Bipolar I disorder, Bipolar

He grew up in the Deep South in a large family of twelve.

Key Points: 
  • He grew up in the Deep South in a large family of twelve.
  • R. B. had several issues at times but lived through them while he was at home with his parents.
  • Home life, school life, love life, professional life, and married life all got covered, coming from the twisted mind of a bipolar individual.
  • Le'Deach's engrossing book is a thought-provoking reflection on his life, career, and family through the lens of his belated bipolar disorder diagnosis.

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

Retrieved on: 
Monday, February 22, 2021
Psychiatric diagnosis, Psychiatry, Mood disorders, Abnormal psychology, Bipolar disorder, Depression, Bipolar spectrum, Bipolar II disorder, Bipolar I disorder, Hypomania, Major depressive disorder, Mania

We believe CAPLYTA has the potential to be an important option for patients in the treatment of bipolar depression.

Key Points: 
  • We believe CAPLYTA has the potential to be an important option for patients in the treatment of bipolar depression.
  • We look forward to bringing CAPLYTA to market, if approved, for the treatment of bipolar depression.
  • Bipolar I and Bipolar II disorder are serious, highly prevalent psychiatric conditions affecting approximately 11 million adults in the U.S.
  • These disorders are characterized by recurrent episodes of mania or hypomania interspersed with episodes of major depression known as Bipolar depression.

New Rapid mood Screener (RMS) Screens for Manic Symptoms and Bipolar I Disorder Features to Address Unmet Clinical Need

Retrieved on: 
Wednesday, February 3, 2021
Psychiatric diagnosis, Mood disorders, Psychiatry, Abnormal psychology, Depression, Bipolar spectrum, Emotion, Bipolar I disorder, Bipolar disorder, Bipolar, Major depressive disorder, Outline of bipolar disorder

The article The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder - is published in Taylor and Francis.com .

Key Points: 
  • The article The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder - is published in Taylor and Francis.com .
  • The novel and pragmatic Rapid Mood Screener (RMS) was developed to screen for manic symptoms and bipolar I disorder features (e.g., age of depression onset) to address this unmet clinical need.
  • "The Rapid Mood Screener provides a systematic approach to screening for bipolar disorder amongst all patients who present with depressive symptoms.
  • Timely screening for bipolar disorder provides the basis for subsequently diagnosing bipolar disorder where applicable and selecting the appropriate treatment.

Review of Bipolar Disorders Confirms Early Diagnosis and Treatment Can Improve Patient Quality of Life

Retrieved on: 
Friday, January 8, 2021
Psychiatric diagnosis, Mood disorders, Psychiatry, Depression, Bipolar spectrum, Psychology, Bipolar Disorders, Abnormal psychology, Bipolar I disorder

The article Bipolar Disorders is published in one of the world's best-known and most reputable scientific journals in medicine - The Lancet.

Key Points: 
  • The article Bipolar Disorders is published in one of the world's best-known and most reputable scientific journals in medicine - The Lancet.
  • The Article contributes to The Lancet's collection of peer-reviewed Seminars and provides a "state-of-the-art overview of bipolar disorders, covering epidemiology, parthenogenesis, diagnosis, treatment, and prevention, while highlighting relevant clinical controversies."
  • Bipolar disorders develop before the age of 25 years in 70% of adults and substantially reduce quality of life and psychosocial functioning across the lifespan.
  • Most individuals with bipolar disorders are predominantly affected by depressive symptoms and episodes.

Bipolar Depression Market is expected to grow with a CAGR of 16.69% during the study period [2017-30] in 7MM, reports DelveInsight

Retrieved on: 
Monday, December 14, 2020
Psychiatric diagnosis, Mood disorders, Depression, Psychiatry, Bipolar spectrum, Abnormal psychology, Bipolar disorder, Human behavior, Bipolar, Major depressive disorder, Cyclothymia, Bipolar I disorder

The research report also covers the current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to evaluate the underlying potential of the Bipolar Depression market.

Key Points: 
  • The research report also covers the current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to evaluate the underlying potential of the Bipolar Depression market.
  • Bipolar Disorder is divided mainly into four subtypes Bipolar Disorder-I, Bipolar Disorder-II, Cyclothymic Disorder, and Bipolar Disorder not otherwise specified (NOS).
  • Study Period of Bipolar Depression Market Report: 3-year Bipolar Depression historical and 11-year forecasted analysis (2017-2030).
  • Analysis: Comparative and conjoint analysis of Bipolar Depression emerging therapies, Attribute Analysis
    Bipolar Depression Market trends, pipeline analysis across different stages of development (Phase III and Phase II), and Bipolar Depression market size by therapies.